CClinicalTrials.gg
CompletedNCT07667140Updated Jun 24, 2026

Standard Post Market Clinical Follow-up (PMCF) Study WSA 2026

An interventional study of In-the-Ear Hearing Aid and Own hearing aid in Hearing Loss, Sensorineural, sponsored by WSAUD A/S. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by WSAUD A/S · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to follow-up on a released low-risk device as part of standard PMCF activities.

Read the detailed description

This is a comparative study which is conducted monocentric at Hoerzentrum Oldenburg, Germany. The focus is to test a released hearing aid and compare this to the subject's own hearing aids with a minimum of 18 adult subjects with mild-to-moderate sensorineural hearing impairement. The subjects, all native German speakers, have 1 appointment of 1-2 hours including a fitting procedure with real-ear measurements and selected standard speech tests and tests of basic hearing-aid related task.

02

Conditions studied

  • Hearing Loss, Sensorineural

Keywords

  • Hearing aid
  • Freiburger
  • Matrix Test
03

In context

Hearing Loss, Sensorineural

371 studies on the registry are indexed under Hearing Loss, Sensorineural; 112 are open to participants now.

This study's enrollment of 24 is below the median of 32 across 264 interventional studies indexed under Hearing Loss, Sensorineural.

Browse Hearing Loss, Sensorineural studies →

Lead sponsor

WSAUD A/S is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Sensorineural hearing loss, mild-to-moderately severe (Pure tone average of 500, 1000, 2000 and 4000 Hz \<65).
  • Hearing loss should fall within fitting range of study hearing aid
  • Subjects should be experienced hearing aid users who have had and used hearing aids daily for at least 1 year.
  • Air-Bone-Gap should be less or equal to 20 dB.
  • Asymmetry between left and right ear should not exceed 20dB for frequencies in the range of 250Hz to 4kHz
  • Healthy (outer and middle) ear
  • Older than 18 years
  • German is mother tongue
  • Able to understand the instructions
  • Willing to participate in laboratory tests and to wear the study HAs at home for 2 weeks
  • Informed consent

Exclusion criteria

Exclusion Criteria:

  • Contraindication for HA treatment
  • Fluctuating or rapidly progressing hearing loss
  • "Central" hearing problems
  • Limited mobility
  • Limited dexterity (in handling the HA)
  • Known psychological or cognitive problems
  • Subjects must not show any injuries or a complete perforation of the ear drum. This must be clarified prior to the beginning of the study by means of otoscopy.
  • Subjects should be in good overall medical condition (e.g., they shall not suffer from dementia) and should not use medical treatments that might affect study results.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Comparison of Study Devices with Own devices

    within subject design: compare Signia Insio 7IX ITC and Signia Silk 7IX to subjects' own hearing aids

    Device: In-the-Ear Hearing Aid · Device: Own hearing aid

Interventions

  • DeviceIn-the-Ear Hearing Aid

    Custom In-the-Ear hearing aid. Form Factor In the Canal (ITC)

  • DeviceOwn hearing aid

    subjects' own hearing aids, any brand, any model

  • DeviceIn-the-Ear Hearing Aid

    Instant Fit Hearing Aid, Form Factor CIC

06

What researchers measure

Primary outcomes

  1. Oldenburg Sentence Test

    The Oldenburg Sentence Test (OLSA) is an audiometric test for determining the speech recognition threshold in quiet and in noise. Sentences of the form name - verb - numeral - adjective - noun are used as speech material. The sequence of words is a random combination from an inventory of 50 words in total. The design of the test prevents memorization of the sentences, so the OLSA can be repeated as often as desired.

    Time frame: Estimated Time Frame 2 weeks (Test conducted at second lab session).

Secondary outcomes

  1. Freiburger Monosyllabic Speech Test

    To investigate speech intelligibility (SI) performance for speech at 65dB in a quiet listening situation, the Freiburger monosyllabic speech test is used which is still the gold standard for Hearing Care Professionals (HCPs) in Germany.

    Time frame: Estimated Time Frame 2 weeks (Test conducted at second lab session).

  2. Match-to-Target

    Investigate how close the study hearing aids fitted with the fitting software to NAL-NL2 Targets match the postulated targets, as measured in-situ with real-ear measurements

    Time frame: Day 1 (Fitting procedure with real-ear measurements is done at first lab session)

  3. Basic user need documentation

    Investigate ability to carry out different hearing-aid related tasks with the test hearing aids documenting if the subjects can carry out the task without support / with support of IFU / with support of Audiologist / Not at all.

    Time frame: One session of approximately 2 hours.

07

Study locations

1 site
  • Hörzentrum Oldenburg gGmbH
    Oldenburg, Germany 26129, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07667140
Lead sponsor
WSAUD A/S
Collaborators
Hoerzentrum Oldenburg
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Mar 25, 2026
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Jun 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion